{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:14:30Z","timestamp":1761488070060,"version":"3.37.3"},"reference-count":14,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":4049,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["100925","351164","CA-73362"],"award-info":[{"award-number":["100925","351164","CA-73362"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011928","name":"Swiss Group for Clinical Cancer Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011928","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1093\/annonc\/mdn385","type":"journal-article","created":{"date-parts":[[2008,6,19]],"date-time":"2008-06-19T00:14:28Z","timestamp":1213834468000},"page":"1837-1841","source":"Crossref","is-referenced-by-count":15,"title":["Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial"],"prefix":"10.1016","volume":"19","author":[{"given":"B.C.","family":"Pestalozzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Quinaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Dolci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Azambuja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.D.","family":"Gelber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Viale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Balil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Nordenskj\u00f6ld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gnant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"L\u00e1ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.A.","family":"Crown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Piccart-Gebhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdn385_bb0010","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists Collaborative Group","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdn385_bb0015","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdm271","article-title":"Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007","volume":"18","author":"Goldhirsch","year":"2007","journal-title":"Ann Oncol."},{"key":"10.1093\/annonc\/mdn385_bb0020","unstructured":"National Comprehensive Cancer Network www.nccn.org (5 June 2008, date last accessed)"},{"key":"10.1093\/annonc\/mdn385_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jnci\/djm287","article-title":"Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial","volume":"100","author":"on behalf of the BIG 02-98 Collaborative Group","year":"2008","journal-title":"J Natl Cancer Inst."},{"key":"10.1093\/annonc\/mdn385_bb0030","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/1097-0142(19950715)76:2<232::AID-CNCR2820760212>3.0.CO;2-0","article-title":"Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel","volume":"76","author":"Freilich","year":"1995","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn385_bb0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1023\/A:1011132609055","article-title":"High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel","volume":"12","author":"Crivellari","year":"2001","journal-title":"Ann Oncol."},{"key":"10.1093\/annonc\/mdn385_bb0040","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/annonc\/mdl064","article-title":"Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)","volume":"17","author":"for the International Breast Cancer Study Group (IBCSG)","year":"2006","journal-title":"Ann Oncol."},{"key":"10.1093\/annonc\/mdn385_bb0045","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/cncr.20530","article-title":"Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment","volume":"101","author":"Gonzales-Angulo","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn385_bb0050","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-004-0999-3","article-title":"Central nervous system metastases in women after multimodality therapy for high risk breast cancer","volume":"88","author":"Carey","year":"2004","journal-title":"Breast Cancer Res Treat."},{"key":"10.1093\/annonc\/mdn385_bb0055","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1002\/cncr.11436","article-title":"Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma","volume":"97","author":"Bendell","year":"2003","journal-title":"Cancer"},{"issue":"11","key":"10.1093\/annonc\/mdn385_bb0060","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/annonc\/mdi371","article-title":"Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy","volume":"16","author":"Burstein","year":"2005","journal-title":"Ann Oncol."},{"key":"10.1093\/annonc\/mdn385_bb0065","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1743-7563.2006.00036.x","article-title":"Central nervous system metastases in women with HER-2 positive metastatic breast cancer after treatment with trastuzumab","volume":"2","author":"Dawson","year":"2006","journal-title":"Asia Pac J Clin Oncol."},{"key":"10.1093\/annonc\/mdn385_bb0070","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1172\/JCI22320","article-title":"Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors","volume":"115","author":"Minn","year":"2005","journal-title":"J Clin Invest."},{"key":"10.1093\/annonc\/mdn385_bb0075","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1200\/JCO.2000.18.11.2349","article-title":"Trastuzumab in CSF","volume":"18","author":"Pestalozzi","year":"2000","journal-title":"J Clin Oncol."}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419401397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419401397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/19\/11\/1837\/507086\/mdn385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:07:52Z","timestamp":1624435672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419401397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0923753419401397"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdn385","relation":{},"ISSN":["0923-7534"],"issn-type":[{"type":"print","value":"0923-7534"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}